Recurrent Clostridium difficile infection: From colonization to cure

被引:74
|
作者
Shields, Kelsey [1 ]
Araujo-Castillo, Roger V. [2 ]
Theethira, Thimmaiah G. [1 ]
Alonso, Carolyn D. [2 ]
Kelly, Ciaran P. [1 ]
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA
关键词
Antibiotic; Fecal microbiota therapy; Infection control; Infectious diarrhea; Nosocomial infection; Toxin; FECAL MICROBIOTA TRANSPLANTATION; IN-VITRO ACTIVITIES; ANTIBIOTIC-ASSOCIATED DIARRHEA; RISK-FACTORS; DOUBLE-BLIND; TOXIN-A; PSEUDOMEMBRANOUS COLITIS; BINARY TOXIN; INTESTINAL MICROBIOTA; TREATMENT STRATEGIES;
D O I
10.1016/j.anaerobe.2015.04.012
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Clostridium difficile infection (CDI) is increasingly prevalent, dangerous and challenging to prevent and manage. Despite intense national and international attention the incidence of primary and of recurrent CDI (PCDI and RCDI, respectively) have risen rapidly throughout the past decade. Of major concern is the increase in cases of RCDI resulting in substantial morbidity, morality and economic burden. RCDI management remains challenging as there is no uniformly effective therapy, no firm consensus on optimal treatment, and reliable data regarding RCDI-specific treatment options is scant. Novel therapeutic strategies are critically needed to rapidly, accurately, and effectively identify and treat patients with, or at-risk for, RCDI. In this review we consider the factors implicated in the epidemiology, pathogenesis and clinical presentation of RCDI, evaluate current management options for RCDI and explore novel and emerging therapies. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:59 / 73
页数:15
相关论文
共 50 条
  • [21] Treatment of Recurrent Clostridium difficile Infection Reply
    Khanna, Sahil
    Gupta, Arjun
    Cifu, Adam S.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (05): : 513 - 513
  • [22] Prevalence of diverticulosis in recurrent Clostridium difficile infection
    Michael J Lipp
    Odelya E Pagovich
    David Rabin
    Albert D Min
    Brett B Bernstein
    World Journal of Gastroenterology, 2010, 16 (03) : 345 - 347
  • [23] Timing of Events in Recurrent Clostridium difficile Infection
    Meade, Charles
    Saffouri, George
    Khanna, Sahil
    Heien, Herb
    Pardi, Darrell
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S109 - S109
  • [24] Prevalence of diverticulosis in recurrent Clostridium difficile infection
    Lipp, Michael J.
    Pagovich, Odelya E.
    Rabin, David
    Min, Albert D.
    Bernstein, Brett B.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (03) : 345 - 347
  • [25] Rifaximin in the treatment of recurrent Clostridium difficile infection
    Mattila, E.
    Arkkila, P.
    Mattila, P. S.
    Tarkka, E.
    Tissari, P.
    Anttila, V. -J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (01) : 122 - 128
  • [26] Bezlotoxumab and Recurrent Clostridium difficile Infection Reply
    Wilcox, Mark
    Dorr, Mary-Beth
    Pedley, Alison
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (16): : 1594 - 1596
  • [27] Risk Factors for Recurrent Clostridium difficile Infection
    Ryu, Han Seung
    Kim, Yong Sung
    Seo, Geom Seog
    Lee, Yu Min
    Choi, Suck Chei
    INTESTINAL RESEARCH, 2012, 10 (02) : 176 - 182
  • [28] Meeting the challenge of recurrent Clostridium difficile infection
    Johnson, Stuart
    JOURNAL OF HOSPITAL MEDICINE, 2012, 7 : S11 - S13
  • [29] Clinical Predictors of Recurrent Clostridium difficile Infection
    Shivashankar, Raina
    Khanna, Sahil
    Kammer, Patricia
    Harmsen, William
    Zinsmeister, Alan
    Baddour, Larry
    Pardi, Darrell
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S213 - S213
  • [30] Recurrent Clostridium difficile infection:: An immunodeficiency state?
    Pardi, Darrell S.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (06) : 672 - 673